Emerging data suggest Retatrutide , a dual activator targeting both incretin and another hormone, could offer a significant development for weight management . Early clinical investigations have demonstrated impressive decreases in visceral fat , potentially outperforming existing weight-loss treatments. Nevertheless , additional assessment is need